Catalog No.
Product Name
Application
Product Information
Citations
-
p38α MAPK Inhibitor
rel-Talmapimod hydrochloride is a selective inhibitor of p38α MAPK, exhibiting an IC50 of 9 nM. By targeting the p38α MAPK pathway, rel-Talmapimod hydrochloride effectively inhibits the secretion of pro-inflammatory factors, including TNFα, IL-1β, IL-6, and VEGF, while also blocking angiogenesis and osteoclast activation. This compound has demonstrated the ability to inhibit the proliferation of multiple myeloma cells and induce apoptosis. It is suitable for research applications involving various hematological malignancies, such as multiple myeloma and myelodysplastic syndrome. -
p38 MAP Inhibitor
R-03201195 is a highly selective inhibitor of p38 MAP kinase, demonstrating an IC50 of 0.7 nM for p38α. It effectively inhibits TNF-α production in THP-1 cells and IL-1β in human whole blood, with IC50 values of 0.25 nM and 0.57 nM, respectively. This reagent is valuable for research applications in inflammatory diseases, particularly rheumatoid arthritis. -
p38α MAPK Inhibitor
BMS-751324 is a selective inhibitor of p38α MAPK, a key regulator in the inflammatory response pathway. This compound demonstrates significant anti-inflammatory effects, as evidenced by its ability to reduce foot swelling and inhibit LPS-induced TNFα production in an arthritic rat model. BMS-751324 is suitable for research applications focused on inflammation, arthritis, and related pathways. -
p38α Inhibitor
P38α-IN-10 is a selective inhibitor of p38α with an IC₅₀ of 230 nM. It effectively suppresses TNF production induced by lipopolysaccharide (LPS), making it a valuable tool for research into inflammatory responses. This compound is particularly relevant for studying conditions such as rheumatoid arthritis and septic shock, contributing to a deeper understanding of their underlying mechanisms. -
p38α MAPK Inhibitor
Talmapimod hydrochloride is a selective inhibitor of p38α MAPK, exhibiting an IC50 of 9 nM. This compound effectively suppresses the secretion of pro-inflammatory cytokines, including TNFα, IL-1β, IL-6, and VEGF, while also inhibiting angiogenesis and osteoclast activation. Talmapimod hydrochloride demonstrates efficacy in inhibiting the growth of multiple myeloma cells and promoting apoptosis, making it a valuable tool for investigating various hematological malignancies, such as multiple myeloma and myelodysplastic syndromes. -
p38 MAPK Inhibitor
SR-318 is a selective inhibitor of p38 MAPK, exhibiting potent activity with IC50 values of 5 nM, 32 nM, and 6.11 µM for p38α, p38β, and p38α/β, respectively. This compound effectively reduces TNF-α release in whole blood, showing an IC50 of 283 nM. SR-318 is utilized in research focusing on anti-cancer and anti-inflammatory pathways, making it valuable for investigating therapeutic strategies in related diseases. -
p38 Inhibitor
TAT-MKK3b is a peptide inhibitor targeted at p38 mitogen-activated protein kinase (MAPK). It effectively inhibits p38 phosphorylation, contributing to its role in modulating cellular stress responses. TAT-MKK3b exhibits renal targeting, reactive oxygen species (ROS) scavenging, and the ability to mitigate ferroptosis. This compound has demonstrated potential in the improvement of acute kidney injury and may help prevent its progression to chronic kidney disease. -
p38 MAPK inhibitor
Losmapimod, also know as GW856553 or GW856553X, is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases. -
p38 MAPK inhibitor
Talmapimod (SCIO-469) is a selective, ATP-competitive p38 inhibitor (IC50 = 9 nM for p38α in vitro). -
p38 MAPK inhibitor
Pamapimod is a novel p38 mitogen-activated protein kinase inhibitor. -
p38 MAPK inhibitor
BMS-582949 Is a Dual Action p38 Kinase Inhibitor Well Suited To Avoid Resistance Mechanisms That Increase p38 Activation in Cells. -
oncometabolite
Fumaric acid is a fundamental unit of nucleic acids.. It is a oncometabolite or an endogenous, cancer causing metabolite. High levels of this organic acid can be found in tumors or biofluids surrounding tumors. Its oncogenic action appears to due to its ability to inhibit prolyl hydroxylase-containing enzymes. -
Antiparasitic
Rafoxanide is a salicylanilide used as an anthelmintic. It is used to treat fluke, hookworm and other infestations. -
p38-α MAPK inhibitor
5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone is isolated from several plants including Zeyhera tuberculosa, Callicarpa japonica, and Kickxia lanigera. -
p38α inhibitor
p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1. -
MK2 Inhibitor
PF-3644022 is a potent and selective mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) inhibitor (Ki =3 nM). -
p38 MAPK inhibitor
SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo. -
nAChR agonist
Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does. -
p38 MAPK inhibitor
DBM 1285 dihydrochloride is a p38 MAPK inhibitor. Supresses p38 phosphorylation and LPS-induced TNF-α production in macrophages and in vivo. - Asiaticoside (Madecassol) is the active chemical component of the plant Centella asiatica. Asiaticoside is used to study potential treatments for wounds and burns.
-
p38 MAPK Activator
MTBT is a p38 MAPK activator with notable anticancer properties. It effectively inhibits tumor cell proliferation, inducing cell cycle arrest and apoptosis. MTBT enhances the phosphorylation of histone H3 at serine residues in cancer cells, thereby facilitating cell cycle arrest in the M phase. The specific p38 MAPK inhibitor Adezmapimod can reverse the cell cycle arrest effects initiated by MTBT, making it a valuable tool in cancer research and therapeutic studies. -
p38 MAPK Agonist
4-Hydroxylonchocarpin is a chalcone compound that acts as an agonist of p38 MAPK. This reagent enhances the phosphorylation of p38 MAPK, JNK, and ERK pathways, thereby promoting the induction of reactive oxygen species (ROS) and apoptosis in liver cancer cells. Additionally, 4-Hydroxylonchocarpin exhibits a diverse range of pharmacological activities, including antibacterial, anticancer, anti-retroviral, anti-tuberculosis, anti-malarial, and anti-inflammatory effects, making it a valuable tool for various research applications in cancer and infectious disease studies. -
p38/JNK Inhibitor
LL-Z1640-4 is a selective inhibitor of p38 and JNK signaling pathways, demonstrating significant efficacy in attenuating their activation in hepatocellular carcinoma (HCC) cells following MLK4 siRNA transfection. This compound effectively reduces reactive oxygen species (ROS) production associated with MLK4 knockdown and subsequently decreases apoptosis in these HCC cells. LL-Z1640-4 serves as a valuable tool for investigating the roles of p38 and JNK in cancer biology and therapeutic interventions. -
p38 MAPK Ihibitor
SB 202190 hydrochloride is a selective inhibitor of the p38 MAP kinase with IC50 values of 50 nM and 100 nM for p38α and p38β, respectively. By binding to the ATP pocket of active recombinant human p38 kinase with a Kd of 38 nM, it demonstrates significant anti-cancer activity. Furthermore, SB 202190 hydrochloride has been shown to induce autophagy, making it a valuable tool for research in cancer biology and signaling pathways related to stress response. -
p38 Kinase/HSP Activator
(±)-Iroxanadine serves as a p38 kinase and heat shock protein (HSP) activator, demonstrating vasculoprotective properties. This compound is pertinent for research into atherosclerosis and various vascular diseases, facilitating studies aimed at understanding the molecular mechanisms underlying these conditions. Its activation of key signaling pathways makes it a valuable tool for exploring therapeutic targets in cardiovascular research. -
p38 MAPK Activator
Iroxanadine hydrochloride is a dual activator of p38 mitogen-activated protein kinase (MAPK) and heat shock proteins (HSPs). It exhibits vasculoprotective properties, making it a valuable tool for investigating mechanisms underlying atherosclerosis and various vascular diseases. This reagent is suitable for research applications focused on the modulation of inflammatory responses and cellular stress pathways. -
p38 MAPK Activator
Iroxanadine hydrobromide is a potent activator of p38 MAPK and HSP proteins. This compounds biological activity focuses on vasculoprotection, making it a valuable tool for investigating atherosclerosis and other vascular diseases. Its dual activation mechanisms provide insights into cellular stress responses and inflammation, making it relevant for research applications in cardiovascular health. -
p38 MAPK Activator
Iroxanadine is a dual activator of p38 MAPK and heat shock proteins (HSPs). It exhibits vasculoprotective properties, making it a valuable reagent for studying atherosclerosis and other vascular diseases. This compound can be utilized in research focusing on inflammatory responses and cardiovascular health, providing insights into the mechanisms underlying these conditions. -
ERK2/p38α MAPK Inhibitor
ERK2/p38α MAPK-IN-1 is a selective inhibitor targeting ERK2 and p38α MAPK, exhibiting an IC50 of 82 μM for ERK2. This compound binds allosterically to both ERK2 and p38α MAPK, influencing their activity through distinct mechanisms. It is primarily utilized in research concerning type 2 diabetes, contributing to studies aimed at understanding the molecular pathways involved in this condition. -
Selective p38α Inhibitor
AMG-548 dihydrochloride is a selective p38α inhibitor with a Ki of 0.5 nM, exhibiting moderate selectivity towards p38β (Ki = 36 nM) and over 1000-fold selectivity against p38γ and p38δ isoforms. This compound demonstrates potent inhibition of TNFα production in whole blood stimulated by LPS, with an IC50 of 3 nM. Additionally, AMG-548 dihydrochloride inhibits Wnt signaling by directly targeting Casein kinase 1 isoforms δ and ε, making it valuable for research in inflammation and signaling pathways. -
Selective p38α Inhibitor
AMG-548 hydrochloride is a selective inhibitor targeting p38α with a Ki of 0.5 nM and shows moderate selectivity for p38β (Ki=36 nM), while exhibiting over 1000-fold selectivity against p38γ and p38δ. This compound effectively inhibits TNFα production in whole blood stimulated by LPS, with an IC50 of 3 nM. Additionally, AMG-548 hydrochloride disrupts Wnt signaling through the direct inhibition of Casein kinase 1 isoforms δ and ε, making it a valuable reagent for studies in inflammation and cancer research. -
p38/CK1 Inhibitor
p38α inhibitor 8 selectively inhibits p38α MAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively. This compound is valuable for studies exploring cellular stress responses and inflammatory pathways, making it a potent tool in cancer research and immunology. Its ability to modulate these kinases presents opportunities for investigating therapeutic strategies in various diseases. -
p38/CK1 Inhibitor
p38α MAPK/CK1δ inhibitor-1 is a selective inhibitor targeting p38α MAPK and CK1δ, exhibiting IC50 values of 0.185 µM and 0.089 µM, respectively. This compound plays a crucial role in modulating cellular responses associated with stress and inflammatory pathways. Its inhibition of both kinases makes it a valuable tool for investigating signaling pathways and therapeutic strategies in various disease models. -
BChE/p38-α MAPK Inhibitor
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor targeting human butyrylcholinesterase (BChE) with an IC50 of 772 nM and p38 α MAPK with an IC50 of 191 nM. This compound significantly reduces the production of pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α in cellular models. BChE/p38-α MAPK-IN-1 demonstrates the potential to ameliorate cognitive impairments induced by scopolamine and alleviate spatial learning deficits in LPS-treated mice, making it a valuable tool for studying Alzheimer's disease by addressing cholinergic deficits and neuroinflammation. -
p38 MAPK Inhibitor
Chicanine is a lignan derived from Schisandra chinensis that functions as a selective inhibitor of p38 MAPK. It effectively inhibits LPS-induced phosphorylation of p38 MAPK, ERK 1/2, and IκB-α, demonstrating significant anti-inflammatory activity. This compound is valuable for research applications centered around inflammation, signaling pathways, and the modulation of MAPK-related processes.
